Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
China Resources Pharmaceutical Group Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 4/6
China Resources Pharmaceutical Group hat ein durchschnittliches jährliches Gewinnwachstum von 2.5% verzeichnet, während die Branche Pharmaceuticals ein Gewinnwachstum gewachsen unter 5.9% jährlich einen Rückgang. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 8% pro Jahr. China Resources Pharmaceutical Group's return on equity is 8.4%, und die Nettomargen betragen 1.6%.
Wichtige Informationen
2.5%
Wachstumsrate der Gewinne
2.5%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 5.6% |
| Wachstumsrate der Einnahmen | 8.0% |
| Eigenkapitalrendite | 8.4% |
| Netto-Marge | 1.6% |
| Letzte Ertragsaktualisierung | 31 Dec 2023 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01
Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued
Feb 14If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%
Jan 17
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Nov 29Aufschlüsselung der Einnahmen und Ausgaben
Wie China Resources Pharmaceutical Group Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Dec 23 | 244,704 | 3,854 | 25,252 | 0 |
| 30 Sep 23 | 239,207 | 3,722 | 24,537 | 0 |
| 30 Jun 23 | 247,532 | 3,852 | 25,157 | 0 |
| 31 Mar 23 | 228,091 | 3,634 | 23,057 | 0 |
| 31 Dec 22 | 218,183 | 3,500 | 21,999 | 0 |
| 30 Sep 22 | 221,487 | 3,724 | 22,247 | 0 |
| 30 Jun 22 | 211,788 | 3,719 | 21,193 | 0 |
| 31 Mar 22 | 196,226 | 3,288 | 19,674 | 0 |
| 31 Dec 21 | 193,021 | 3,072 | 19,393 | 0 |
| 30 Sep 21 | 191,495 | 2,869 | 19,667 | 0 |
| 30 Jun 21 | 187,554 | 2,626 | 19,701 | 0 |
| 31 Mar 21 | 179,512 | 2,720 | 19,092 | 0 |
| 31 Dec 20 | 168,762 | 2,776 | 18,197 | 0 |
| 30 Sep 20 | 171,873 | 2,683 | 19,137 | 0 |
| 30 Jun 20 | 174,956 | 2,578 | 20,122 | 0 |
| 31 Mar 20 | 181,054 | 2,793 | 21,233 | 0 |
| 31 Dec 19 | 182,690 | 2,937 | 21,813 | 0 |
| 30 Sep 19 | 183,417 | 3,670 | 21,984 | 0 |
| 30 Jun 19 | 173,938 | 4,187 | 20,930 | 0 |
| 31 Mar 19 | 165,679 | 3,737 | 20,069 | 0 |
| 31 Dec 18 | 166,626 | 3,494 | 20,322 | 0 |
| 30 Sep 18 | 163,734 | 3,466 | 19,540 | 0 |
| 30 Jun 18 | 154,852 | 3,309 | 18,062 | 0 |
| 31 Mar 18 | 142,296 | 2,959 | 15,795 | 0 |
| 31 Dec 17 | 143,688 | 2,901 | 15,087 | 0 |
| 30 Sep 17 | 143,252 | 2,759 | 14,277 | 0 |
| 30 Jun 17 | 142,276 | 2,602 | 13,380 | 0 |
| 31 Mar 17 | 142,003 | 2,577 | 13,395 | 0 |
| 31 Dec 16 | 140,316 | 2,526 | 13,279 | 0 |
| 30 Sep 16 | 132,253 | 2,161 | 12,534 | 0 |
| 30 Jun 16 | 129,313 | 1,889 | 12,274 | 0 |
| 31 Mar 16 | 123,770 | 2,103 | 11,766 | 0 |
| 31 Dec 15 | 122,785 | 2,388 | 11,692 | 0 |
| 31 Dec 14 | 108,575 | 2,116 | 9,955 | 0 |
| 31 Dec 13 | 91,313 | 2,061 | 9,248 | 0 |
Qualität der Erträge: 3320 hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: 3320Die aktuellen Gewinnspannen (1.6%) sind niedriger als im letzten Jahr (1.6%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 3320In den letzten 5 Jahren sind die Gewinne von 2.5% jährlich gestiegen.
Beschleunigtes Wachstum: 3320Das Gewinnwachstum des Unternehmens im letzten Jahr (10.1%) übertrifft seinen 5-Jahres-Durchschnitt (2.5% pro Jahr).
Erträge im Vergleich zur Industrie: 3320 Das Gewinnwachstum im vergangenen Jahr (10.1%) übertraf das der Branche Pharmaceuticals 1.3%.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 3320Die Eigenkapitalrendite des Unternehmens (8.4%) wird als niedrig angesehen.